Key clinical point: Fecal microbiota transplant was safe and showed suggestions of effectiveness in a pilot, phase 1 study of patients with recurrent hepatic encephalopathy.
Major finding: Average Offtime+Ontime in the EncephalApp test fell by a clinically meaningful 51 seconds from baseline to follow-up.
Study details: A single-center, phase 1 safety study with 20 randomized patients.
Disclosures: Dr. Bajaj had no relevant disclosures.
Bajaj JS et al. J Hepatol. 2019 April;70(1):e55.